Cargando…

PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade

Hypercholesterolemia is one of the main risk factors for coronary heart disease and significantly contributes to the high mortality associated with cardiovascular diseases. Statin therapy represents the gold standard in the reduction of low-density lipoprotein cholesterol concentration. Nevertheless...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaworski, Krzysztof, Jankowski, Piotr, Kosior, Dariusz A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510512/
https://www.ncbi.nlm.nih.gov/pubmed/28721159
http://dx.doi.org/10.5114/aoms.2017.65239
_version_ 1783250198218145792
author Jaworski, Krzysztof
Jankowski, Piotr
Kosior, Dariusz A.
author_facet Jaworski, Krzysztof
Jankowski, Piotr
Kosior, Dariusz A.
author_sort Jaworski, Krzysztof
collection PubMed
description Hypercholesterolemia is one of the main risk factors for coronary heart disease and significantly contributes to the high mortality associated with cardiovascular diseases. Statin therapy represents the gold standard in the reduction of low-density lipoprotein cholesterol concentration. Nevertheless, many patients still cannot achieve the recommended target levels, due to either inadequate effectiveness or intolerance of these drugs. Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a promising option in lipid-lowering treatment. After confirmation of their efficacy and safety in clinical trials, evolocumab and alirocumab received approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for introduction into clinical practice. In this review, we present a history of the development and mechanisms of action, as well as the results of the most important studies concerning PCSK9 inhibitors.
format Online
Article
Text
id pubmed-5510512
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-55105122017-07-18 PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade Jaworski, Krzysztof Jankowski, Piotr Kosior, Dariusz A. Arch Med Sci State of the Art Paper Hypercholesterolemia is one of the main risk factors for coronary heart disease and significantly contributes to the high mortality associated with cardiovascular diseases. Statin therapy represents the gold standard in the reduction of low-density lipoprotein cholesterol concentration. Nevertheless, many patients still cannot achieve the recommended target levels, due to either inadequate effectiveness or intolerance of these drugs. Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a promising option in lipid-lowering treatment. After confirmation of their efficacy and safety in clinical trials, evolocumab and alirocumab received approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for introduction into clinical practice. In this review, we present a history of the development and mechanisms of action, as well as the results of the most important studies concerning PCSK9 inhibitors. Termedia Publishing House 2017-01-19 2017-06 /pmc/articles/PMC5510512/ /pubmed/28721159 http://dx.doi.org/10.5114/aoms.2017.65239 Text en Copyright: © 2017 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle State of the Art Paper
Jaworski, Krzysztof
Jankowski, Piotr
Kosior, Dariusz A.
PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
title PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
title_full PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
title_fullStr PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
title_full_unstemmed PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
title_short PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
title_sort pcsk9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
topic State of the Art Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510512/
https://www.ncbi.nlm.nih.gov/pubmed/28721159
http://dx.doi.org/10.5114/aoms.2017.65239
work_keys_str_mv AT jaworskikrzysztof pcsk9inhibitorsfromdiscoveryofasinglemutationtoagroundbreakingtherapyoflipiddisordersinonedecade
AT jankowskipiotr pcsk9inhibitorsfromdiscoveryofasinglemutationtoagroundbreakingtherapyoflipiddisordersinonedecade
AT kosiordariusza pcsk9inhibitorsfromdiscoveryofasinglemutationtoagroundbreakingtherapyoflipiddisordersinonedecade